Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0JLDZY)
| ADC Name |
SIBP-A13
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
SIBP-A13
Click to Show/Hide
|
|||||
| Organization |
Shanghai Institute of Biological Products (Sinopharm) (Originator)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Anti-HER3 mAb
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-3 (HER3)
|
Antigen Info | ||||
| Payload Name |
DXd
|
Payload Info | ||||
| Payload Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Mc-VASGFG
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Disease Name | Phase 1 | Phase 2 | Phase 3 | Approved |
|---|---|---|---|---|
| Lung cancer | ||||
| Breast cancer | ||||
| Head and neck cancer | ||||
| Unspecific solid tumor |